<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121793">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517191</url>
  </required_header>
  <id_info>
    <org_study_id>SOS-VE01</org_study_id>
    <nct_id>NCT01517191</nct_id>
  </id_info>
  <brief_title>Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults</brief_title>
  <acronym>SOS-VE01</acronym>
  <official_title>Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dalhousie University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This surveillance study will include all consenting adults hospitalized with influenza
      (cases) at the SOS network of hospitals as well as influenza negative patients(controls), to
      assess vaccine effectiveness in each group. Both groups will be followed throughout their
      hospitalization and for 30 days post discharge to monitor severity of illness and outcomes
      following their illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research
      Network (PCIRN) is a collaborative research network which brings together over 100
      investigators in over 40 institutions to evaluate all factors relevant to the introduction
      of a pandemic influenza vaccine in Canada. The Serious Outcomes Surveillance (SOS) Network
      within PCIRN was established in 2009 to plan for evaluation of influenza vaccine safety and
      effectiveness. Vaccine effectiveness studies are critical in assessing vaccine effectiveness
      under real world conditions and in assessing vaccine effectiveness in the prevention of
      severe outcomes. Establishing the methodology and infrastructure for real-time field
      assessment of vaccine effectiveness is crucial to inform policy recommendations for the
      optimal use of resources, including vaccines.

      This study will include all consenting adult patients hospitalized at one of the SOS Network
      hospitals during influenza season who test positive for influenza (cases). In addition two
      influenza negative controls will be matched to each case to measure differences in vaccine
      effectiveness. Specific study aims are:

        1. To determine the effectiveness of trivalent influenza vaccination (TIV in general, and
           GSK TIV in particular) in preventing influenza-associated hospitalization in adults ≥
           65 years,

        2. To determine the effectiveness of influenza vaccination in preventing
           influenza-associated death in adults ≥ 65 years

        3. To determine the effectiveness of influenza vaccination in preventing
           influenza-associated hospitalization and death in adults &lt; 65 years

        4. To characterize the burden of disease, clinical outcomes, and resource utilization
           associated with influenza A and influenza B lineages

        5. To examine clinical and immunologic factors impacting on severity of disease and
           influenza vaccine effectiveness in adults
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the burden of influenza disease and influenza vaccine effectiveness.</measure>
    <time_frame>1 Year</time_frame>
    <description>Occurrence of any PCR-confirmed influenza virus infection in vaccinated (&gt;14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 65 years of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the burden of influenza disease and influenza vaccine effectiveness.</measure>
    <time_frame>1 Year</time_frame>
    <description>Occurrence of any PCR-confirmed influenza virus infection in vaccinated (&gt;14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 16 years of age</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza Positive Case</arm_group_label>
    <description>Influenza cases are hospitalized adults who have tested positive for influenza.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza Negative Control</arm_group_label>
    <description>Control Controls are hospitalized adults who have tested negative for influenza.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Nasopharyngeal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This observational study is open to adults admitted to hospital with test postitive
        influenza or with an influenza like illness who test negative.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥ 16 years of age admitted to participating SOS Network hospitals with
             the following admitting diagnoses will be eligible for screening within 5 days of
             admission:

          -  community-acquired pneumonia

          -  acute exacerbation of chronic obstructive pulmonary disease (AECOPD) or asthma

          -  unexplained sepsis

          -  Any other respiratory infection or diagnosis Or any respiratory or influenza-like
             symptom )(eg dyspnea, cough, sore throat, myalgia, arthralgia, fever)

        One day per week, beginning when the local laboratory reports influenza positivity rates
        of ≥ 5% of all tests submitted, patients admitted with the following will also be
        screened:

          -  Acute coronary syndrome (eg myocardial infarction, unstable angina) with a triage
             temperature ≥37.5°C

          -  Any other cardiac diagnosis (eg atrial fibrillation, other arrhythmia, myocarditis)
             with a triage temperature ≥ 37.5°C

          -  Stroke with a triage temperature ≥37.5°C

        Exclusion Criteria:

          -  Patients whose reason for admission was clearly unrelated to the presence of
             influenza (for example, patients admitted due to trauma, elective surgery, or
             patients who have an alternative diagnosis that is clearly not cardiac, respiratory,
             or neurologic, e.g. cellulitis, intra-abdominal process, or gastrointestinal
             bleeding)

          -  Patients testing positive (cases) for whom immunization status cannot be ascertained
             will be excluded from the vaccine effectiveness analysis component of the study,
             however, they will still be enrolled and will be included in the burden of influenza

          -  Patients testing negative for influenza (controls) for whom immunization status
             cannot be ascertained (by verbal self report or other source) will not be eligible
             for enrolment

          -  No children in care will be enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelly A McNeil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelly A McNeil, MD, FRCPC</last_name>
    <phone>902-470-8141</phone>
    <email>shelly.mcneil@cdha.nshealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vancouver General</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant Stiver, MD</last_name>
      <phone>604-875-4146</phone>
      <email>gstiver@interchange.ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>William Bowie, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Light, MD</last_name>
      <phone>204-237-2948</phone>
      <email>light@cc.umanitoba.ca</email>
    </contact>
    <contact_backup>
      <last_name>Phillipe Lagace Wiens, MD</last_name>
      <email>plagacewiens@dsmanitoba.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Webster, MD</last_name>
      <phone>506-648-6807</phone>
      <email>Duncan.webster@horizonNB.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QEII Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly A McNeil, MD</last_name>
      <phone>902-470-8141</phone>
      <email>Shelly.mcneil@cdha.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Shelly A McNeil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Loeb, MD</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>26066</phone_ext>
      <email>loebm@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jennie Johnston, MD</last_name>
      <email>johnsj48@mcmaster.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ottawa General</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne McCarthy, MD</last_name>
      <phone>613-737-8184</phone>
      <email>amccarthy@Ottawahospital.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison McGeer, MD</last_name>
      <phone>(416) 586-3118</phone>
      <email>amcgeer@mtsinai.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUCH</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makeda Semret, MD</last_name>
      <phone>514-345-3511</phone>
      <email>makeda.semret@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loius Valiquette, MD</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>12568</phone_ext>
      <email>Louis.Valiquette@USherbrooke.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUl/CHUQ</name>
      <address>
        <city>Quebec</city>
        <zip>Canada</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Boivin, MD</last_name>
      <phone>(418) 654-2705</phone>
      <email>Guy.boivin@crchul.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Trottier, MD</last_name>
      <email>Sylvie.trottier@crchul.ulaval.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 20, 2012</lastchanged_date>
  <firstreceived_date>January 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Respiratory Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
